MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling

AIMS: Heart failure is a major complication in cancer treatment due to the cardiotoxic effects of anticancer drugs, especially from the anthracyclines such as doxorubicin (DXR). DXR enhances oxidative stress and stimulates matrix metalloproteinase-2 (MMP-2) in cardiomyocytes. We investigated whether...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Res
Autors principals: Chan, Brandon Y H, Roczkowsky, Andrej, Cho, Woo Jung, Poirier, Mathieu, Sergi, Consolato, Keschrumrus, Vic, Churko, Jared M, Granzier, Henk, Schulz, Richard
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7797218/
https://ncbi.nlm.nih.gov/pubmed/31995179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvaa017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars